ArticleBMJ neurology open2026
Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021).
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Device-aided therapies (DAT) have significantly improved the management of Parkinson's disease (PD). They now include deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG) infusion, continuous subcutaneous apomorphine infusion (CSAI), subcutaneous foslevodopa/foscarbidopa and levodopa-entacapone-carbidopa intestinal gel (LECIG) infusions. Despite established clinical benefits, disparities in DAT access and use have been reported across Europe and the USA. The PARKinson's Device-Aided-Therapies (PARK-DAT) study aimed to evaluate access to and use of DAT (DBS, LCIG and CSAI) for PD in France between 2015 and 2021 using data from the French national administrative healthcare database ( Methods: PARK-DAT is a nationwide, retrospective observational study. Patients with PD who initiated any DAT for the first time between 2015 and 2021 were identified using an established algorithm and codes within the SNDS. Standardised incidences of DAT initiation were calculated by study period and geographical region. Results: Between 2015 and 2021 8829 patients with PD (mean age 68.7±10.3 years; 43.4% women) initiated DAT representing a 41.8% overall increase between 2015 and 2021. CSAI was the most frequently initiated therapy (6873 patients; +58.9%), followed by DBS (1592 patients; -20.7%) and LCIG (364 patients; +152.9%). Most DAT prescriptions originated from hospital centres (74.6%). Few therapy switches or combinations were observed, mainly involving CSAI. Regional analyses suggest incidence disparities in DAT access. Discussion: Unlike patterns observed in other countries, CSAI was the predominant DAT in France, while DBS use declined. Features of the French healthcare system, including favourable reimbursement and broad access to home nursing services, may account for this distinctive distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.